Company intelligence / Profile preview

Immune Design

Seattle, Washington, United Statesimmunedesign.com ↗

Ownership: Private
Employees: ~50
Development stage: Other

Overview

Immune Design developed two synergistic immunotherapy platforms with clinical programs ranging from preclinical to randomized Phase 2. Their lead candidate G100 showed clinical benefit as an intratumoral TLR4 agonist in multiple tumor types. The company also had ongoing pharmaceutical collaborations for infectious disease and allergy indications

Therapeutic areas: OncologyImmunologyInfectious Diseases
Modalities: Vaccinesbiologicsimmunotherapies (notably *in vivo* dendritic cell-targeting vectors and TLR4 agonists)
Industry: Biotech

Partnerships

Collaborations with pharmaceutical companies for development of infectious disease and allergy indications; three oncology clinical collaborations combining their agents with partners’ therapies as of late-stage operations before the Merck acquisition

Beyond the preview

Go deeper on Immune Design.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Immune Design.